Evaluation of the Efficacy and the Safety of FOLFIRINOX3 Bevacizumab Treatment in patients with colorectal cancer
Phase 1
Active, not recruiting
- Conditions
- Patients with metastatic colorectal cancerTherapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Registration Number
- CTIS2024-515908-39-00
- Lead Sponsor
- Centr Georges Francois Leclerc
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Recruiting
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie FOLFIRINOX3 and Bevacizumab synergy in metastatic colorectal cancer?
How does FOLFIRINOX3 compare to standard-of-care regimens in RAS-mutant metastatic CRC patients?
Which biomarkers correlate with response to FOLFIRINOX3 plus Bevacizumab in VEGF-targeted therapy?
What are the most common adverse events associated with FOLFIRINOX3 and Bevacizumab combination therapy?
Are there alternative anti-angiogenic agents being tested with FOLFIRINOX in digestive system malignancies?